Insmed Incorporated(INSM)

NASDAQ Global Select
Sector: Healthcare | Industry: Medical - Pharmaceuticals
Insmed Incorporated logo

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Latest News & Analysis

Female scientist examining samples with a microscope in a modern laboratory
Jun 16, 2025

Insmed (INSM) Analysis: Pipeline Success & Strategic Capital Raise

Insmed's stock surged on clinical trial success and a strategic capital raise, signaling a transformative period for the biopharmaceutical firm.

Read more →
Biopharmaceutical laboratory equipment on a reflective surface with a soft purple gradient background
Jun 12, 2025

Insmed (INSM) Capital Raise and PAH Trial Success: A Deep Dive

Insmed's recent $750M capital raise and positive PAH trial results signal strong growth potential, redefining its biopharmaceutical market position.

Read more →
Insmed (INSM) stock price surge driven by positive Phase 2b clinical trial results for its Pulmonary Arterial Hypertension (PAH) therapy, TPIP, and strategic capital raise, highlighting growth in biotech and pharmaceutical innovation.
Jun 11, 2025

Insmed Stock Jumps on Strong PAH Trial Results, Capital Raise

Insmed's stock surged following positive PAH trial results, exceeding expectations. A $650M offering aims to fund pipeline growth amid shifting market dynamics.

Read more →
Insmed (INSM) analysis: FDA review of brensocatib, ARIKAYCE sales growth, ATS 2025 data, and healthcare policy impacts on this rare disease treatment company.
Mar 25, 2025

Insmed (INSM): Brensocatib's FDA Path, ARIKAYCE Growth, and ATS 2025 Insights

Analysis of Insmed's brensocatib FDA review, ARIKAYCE sales, and ATS 2025 insights. Strategic focus, market performance, and healthcare policy impacts explored.

Read more →
Insmed's future: Brensocatib FDA approval, ARIKAYCE growth, and financial outlook. Investment analysis, pipeline review, competitive advantages in bronchiectasis and MAC lung disease.
Mar 3, 2025

Insmed (INSM): Brensocatib's FDA Journey, ARIKAYCE's Ascent, and Future Prospects

Insmed (INSM) awaits a pivotal FDA decision on brensocatib for bronchiectasis. Strong ARIKAYCE growth contrasts with wider losses, shaping its future prospects.

Read more →
Insmed (INSM) stock analysis: Brensocatib FDA review, ARIKAYCE growth, and financial outlook - investment insights.
Feb 28, 2025

Insmed (INSM): Brensocatib FDA Review, ARIKAYCE Growth, and Financial Outlook

Insmed's brensocatib nears potential FDA approval amid strong ARIKAYCE sales. Q4 losses spark caution, but analysts see potential. A deep dive into INSM's outlook.

Read more →
Insmed (INSM) Stock Analysis: Brensocatib FDA Approval, ARIKAYCE Performance, and Financial Outlook
Feb 27, 2025

Insmed (INSM): Brensocatib's FDA Decision Looms - A Comprehensive Analysis

Insmed awaits FDA decision on brensocatib (August 12, 2025). No advisory committee suggests streamlined approval. Q4 loss wider, but ARIKAYCE strong. Key insights inside.

Read more →
Insmed (INSM) stock analysis: FDA update on Brensocatib, ARIKAYCE sales performance, and market outlook for Insmed's financial health.
Feb 25, 2025

Insmed (INSM): Brensocatib FDA Update, ARIKAYCE Sales, and Market Outlook

Analysis of Insmed (INSM): FDA update on Brensocatib, ARIKAYCE sales, international strategies, and Q4 2024 financials. Actionable insights for investors.

Read more →